Citius Oncology, Inc. - Common Stock CTOR 深 沪
已收盘 08-22 16:00:00 美东时间
1.75
+0.120
+7.36%
华盛通- 最 高1.80
- 今 开1.63
- 成交量 28.30万股
- 最 低 1.63
- 昨 收 1.63
- 总市值 1.25亿
- 52周最高 6.19
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.5506
- 委 比 37.34%
- 总股本 7155.24万
- 历史最高 49.00
- 量 比 2.73
- 振 幅 10.43%
- 历史最低 0.00
- 每 手 1
- 风险率 0.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Citius Oncology Deploys AI Platform To Bolster Commercial Strategy Ahead Of LYMPHIR Launch
Proprietary model informs targeted sales and marketing strategies with feedback loop thataugments precision and impact of targeting and engagementCRANFORD, N.J., Aug. 22, 2025 /PRNewswire/ -- Citius Oncology, Inc.
08-22 20:49
Citius Oncology Conducts Public Offering of Stock
The latest announcement is out from Citius Oncology ( ($CTOR) ). On July 17, 20...
08-19 05:48
Citius Oncology Q3 EPS $(0.08) Beats $(0.15) Estimate
Citius Oncology (NASDAQ:CTOR) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.15) by 46.67 percent. This is a 14.29 percent decrease over losses of $(0.07) per share from
08-13 04:34
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
NetworkNewsWire Editorial Coverage NEW YORK, Aug. 6, 2025 /PRNewswire/ -- As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, partic...
08-06 20:30
Cheetah Mobile to Take 75.8% Stake in Robotic Arm Maker UFACTORY in $13.7M Deal
Cheetah Mobile Inc. (NYSE:CMCM) ("Cheetah Mobile" or the "Company"), a China-based IT company, today announced that one of its majority-owned subsidiaries has signed a definitive agreement to acquire an equity interest
07-28 17:03
Citius Oncology Announces Pricing of $9.0 Million Public Offering
CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: ...
07-16 21:15
Cencora distribution deal boosts Citius shares
Citius Pharmaceuticals (NASDAQ:CTXR) traded higher in the premarket on Tuesday after the company announced that its majority-owned subsidiary, Citius Oncology (NASDAQ:CTOR), reached a distribution ser...
07-15 20:56
Citius Oncology Partners With Cencora To Boost Commercial Launch And Distribution Of FDA-Approved Immunotherapy LYMPHIR
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™CRANFORD, N.J., July 15, 2025 /PRNewswire/ --
07-15 20:35
Citius Oncology launches $15M equity and warrant offering; shares down
Citius Oncology (NASDAQ:CTOR) is offering up to $15M in common stock and accompanying warrants. The offering includes up to $15M in pre-funded warrants and up to $15M in regular warrants, each convert...
07-14 22:51
